Targeting Neuroserpin-plasmin Interactions To Protect The Retina In Glaucoma
Funder
National Health and Medical Research Council
Funding Amount
$648,965.00
Summary
Glaucoma causes blindness and despite our best treatment many patients continue to progress. A new approach is needed to protect the cells that die in the retina. We have established that a common protease – plasmin – is involved in the process, and a protein that normally regulates it – neuroserpin – is downregulated in the disease. We aim to modify neuroserpin using an ocular gene therapy approach and show it could be used as a novel therapy in glaucoma.
How Does Glucose Protect The Retina And Optic Nerve Against Ischaemia?
Funder
National Health and Medical Research Council
Funding Amount
$418,171.00
Summary
Raised blood sugar levels are generally considered to be bad for nerve cells, especially those in the eye. But we have made a groundbreaking discovery finding that in the short-term, sugar can rescue nerve cells in the eye from death caused by lack of blood flow. In this project we will investigate how this remarkable effect is achieved.
Targeting At Risk Relatives Of Glaucoma Patients For Early Diagnosis And Treatment (TARRGET)
Funder
National Health and Medical Research Council
Funding Amount
$595,375.00
Summary
Glaucoma is the second leading cause of blindness in Australia but early detection and treatment can prevent blindness. We will recruit patients with advanced glaucoma from an Australia wide registry and refer their close relatives to have an eye exam and genetic testing to see if they are at risk of glaucoma. We will evaluate how a coordinator can improve the uptake of this screening program referring people to local eye care providers and in rural WA providing screening in 16 remote locations.
Saving The Optic Nerve : Manipulating The Shp2-Caveolin Axis
Funder
National Health and Medical Research Council
Funding Amount
$546,395.00
Summary
Glaucoma is a leading cause of blindness with many patients experiencing progressive vision loss despite treatment. We propose to use gene therapy techniques to manipulate the signalling pathway of Brain Derived Neurotrophic Factor and its receptor, along with biochemical and functional approaches to understand the mechanisms of glaucoma mediated eye damage and to develop new therapeutic strategies.
Translating Genetic Determinants Of Glaucoma Into Better Diagnosis And Treatment
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
Glaucoma is the leading cause of irreversible blindness worldwide. By 2020, it will affect 80 million people, and in Australia over the next decade, the overall cost of glaucoma will reach $4.3 billion per annum. This Program will use genetic advances to personalise treatment. Blindness will be prevented in individuals at highest risk, new ways to treat patients will be developed, and better outcomes for patients will result from less treatment and monitoring of low risk cases.
Glaucoma Causes Secondary Neurodegeneration In The Brain
Funder
National Health and Medical Research Council
Funding Amount
$380,891.00
Summary
Glaucoma is one of the commonest causes of irreversible blindness worldwide. The optic nerve have been considered as the primary site of glaucomatous damage. However, recent evidence suggests that glaucoma may not merely be an eye disease, because secondary changes have also been observed in the higher visual centres in glaucoma patients. In this proposed study, topographically related degeneration along the visual pathway will be monitored using advanced MRI technology.
Seeing Clearly: Examining The Consequences Of Glaucoma For The Human Brain
Funder
National Health and Medical Research Council
Funding Amount
$439,694.00
Summary
Glaucoma is a major cause of blindness. Many people are unaware of the resulting blind region (scotoma) and fail to get an eye test, allowing the disease to progress. This project aims to see how the brain ‘fills in’ the scotoma, and the effect of different scotoma types, using vision tests, brain imaging, and behavioural methods. The results will tell us whether the region around a scotoma helps or hinders the person's remaining vision, which is critical for activities such as driving.